UNSPSC 51373444: Codeine/guaifenesin/pseudoephedrine/triprolidine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373444 Codeine/guaifenesin/pseudoephedrine/triprolidine is a Commodity code under which state and local governments procure pharmaceutical products and related healthcare supplies, though recent solicitations show a mismatch between the code's nominal scope and actual buying patterns. The Washington State Department of Corrections issued RFQ RFQQK13020 in September 2026 seeking parenteral products, services, and equipment — specifically parenteral nutrition solutions (TPN and PPN), intravenous solutions, and other parenteral products including controlled substances for incarcerated individuals — rather than the specific codeine-based combination drug the code nominally describes. The Seminole County, Florida procurement (IFB 60459723LAS, posted June 2026) targeted naloxone and drug deactivation systems, similarly unrelated to the code's stated pharmaceutical composition. State and local buyers tagging these opportunities with UNSPSC 51373444 appear to be using the code as a catch-all for pharmaceutical procurement rather than as a precise match to the combination drug itself. The issuing bodies span state correctional agencies and county health departments, reflecting the healthcare and public-safety focus of the actual buying activity.

Geographic activity centers on Washington State and Florida based on recent solicitations. The Washington State Department of Corrections RFQ (due October 7, 2026) encompasses eight correctional facilities across three regions — West, Central, and East — with DOC planning to award up to three contractors per region for an initial term running November 26, 2026 through June 30, 2030, with fixed pricing for the first two years. The Seminole County opportunity calls for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries through an initial two-year term plus one-year renewal option. Neither opportunity directly aligns with the code's nominal pharmaceutical scope, suggesting either systematic miscoding by state and local procurement offices or the code's use as a broader pharmaceutical-procurement bucket. Firms should verify the actual commodity alignment before pursuing opportunities posted under this code.